Lahn Michael M相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

一项针对新诊断恶性胶质瘤患者的 1b/2a 期研究，评估了转化生长因子-β受体I小分子抑制剂 galunisertib 与基于替莫唑胺的标准放化疗方案联合治疗的疗效。

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-020-00910-9

Wick, Antje; Desjardins, Annick; Suarez, Cristina; Forsyth, Peter; Gueorguieva, Ivelina; Burkholder, Tiana; Cleverly, Ann Louise; Estrem, Shawn T; Wang, Shuaicheng; Lahn, Michael M; Guba, Susan C; Capper, David; Rodon, Jordi

发表日期：2020

文献求助收藏

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

一项针对日本不可切除肝细胞癌患者的转化生长因子-β受体I抑制剂galunisertib联合索拉非尼的1b期研究

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-018-0636-3

Ikeda, Masafumi; Morimoto, Manabu; Tajimi, Masaomi; Inoue, Koichi; Benhadji, Karim A; Lahn, Michael M F; Sakai, Daisuke

细胞生物学

发表日期：2019

文献求助收藏

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Galunisertib联合吉西他滨对比吉西他滨单药治疗不可切除胰腺癌患者的一线疗效

期刊:British Journal of Cancer

影响因子:6.8

doi:10.1038/s41416-018-0246-z

Melisi, Davide; Garcia-Carbonero, Rocio; Macarulla, Teresa; Pezet, Denis; Deplanque, Gael; Fuchs, Martin; Trojan, Jorg; Oettle, Helmut; Kozloff, Mark; Cleverly, Ann; Smith, Claire; Estrem, Shawn T; Gueorguieva, Ivelina; Lahn, Michael M F; Blunt, Al; Benhadji, Karim A; Tabernero, Josep

发表日期：2018

文献求助收藏

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

一项 II 期随机研究，比较了加鲁尼塞替单药治疗或加鲁尼塞替联合洛莫司汀治疗与洛莫司汀单药治疗在复发性胶质母细胞瘤患者中的疗效。

期刊:Neuro-Oncology

影响因子:13.4

doi:10.1093/neuonc/now009

Brandes, Alba A; Carpentier, Antoine F; Kesari, Santosh; Sepulveda-Sanchez, Juan M; Wheeler, Helen R; Chinot, Olivier; Cher, Lawrence; Steinbach, Joachim P; Capper, David; Specenier, Pol; Rodon, Jordi; Cleverly, Ann; Smith, Claire; Gueorguieva, Ivelina; Miles, Colin; Guba, Susan C; Desaiah, Durisala; Lahn, Michael M; Wick, Wolfgang

细胞生物学

发表日期：2016

文献求助收藏

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

三种不同制剂的加鲁尼塞替单药治疗晚期或转移性癌症患者的相对生物利用度

期刊:Drugs in Context

影响因子:2.8

doi:10.7573/dic.212303

Gueorguieva, Ivelina; Cleverly, Ann; Desaiah, Durisala; Azaro, Analia; Seoane, Joan; Braña, Irene; Sicart, Elisabet; Miles, Colin; Lahn, Michael M; Mitchell, Malcolm I; Rodon, Jordi

发表日期：2016

文献求助收藏

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

galunisertib（LY2157299 一水合物）是一种转化生长因子-β信号通路的小分子抑制剂，目前正在进行临床开发

期刊:Drug Design Development and Therapy

影响因子:5.1

doi:10.2147/DDDT.S86621

Herbertz Stephan, Sawyer J Scott, Stauber Anja J, Gueorguieva Ivelina, Driscoll Kyla E, Estrem Shawn T, Cleverly Ann L, Desaiah Durisala, Guba Susan C, Benhadji Karim A, Slapak Christopher A, Lahn Michael M

发表日期：2015

文献求助收藏

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

在首次人体剂量研究中，TGF-β受体I激酶抑制剂LY2157299一水合物对癌症患者的心脏安全性

期刊:Cardiovascular Toxicology

影响因子:3.7

doi:10.1007/s12012-014-9297-4

Kovacs, Richard J; Maldonado, Giuliana; Azaro, Analia; Fernández, Maria S; Romero, Federico L; Sepulveda-Sánchez, Juan M; Corretti, Mary; Carducci, Michael; Dolan, Melda; Gueorguieva, Ivelina; Cleverly, Ann L; Pillay, N Sokalingum; Baselga, Jose; Lahn, Michael M

发表日期：2015

文献求助收藏

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

美国真实临床实践中胶质母细胞瘤的治疗模式、生存率和医疗资源利用情况

期刊:Drugs in Context

影响因子:2.8

doi:10.7573/dic.212274

Girvan, Allicia C; Carter, Gebra C; Li, Li; Kaltenboeck, Anna; Ivanova, Jasmina; Koh, Maria; Stevens, Jessi; Hayes-Larson, Eleanor; Lahn, Michael M

细胞生物学

发表日期：2015

文献求助收藏

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

在针对晚期癌症患者的 I 期研究中，对转化生长因子-β 受体 I 激酶抑制剂 galunisertib 进行药代动力学、药效学和生物标志物评估

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-014-0192-4

Rodón, Jordi; Carducci, Michael; Sepulveda-Sánchez, Juan M; Azaro, Analía; Calvo, Emiliano; Seoane, Joan; Braña, Irene; Sicart, Elisabet; Gueorguieva, Ivelina; Cleverly, Ann; Pillay, N Sokalingum; Desaiah, Durisala; Estrem, Shawn T; Paz-Ares, Luis; Holdhoff, Matthias; Blakeley, Jaishri; Lahn, Michael M; Baselga, Jose

发表日期：2015

文献求助收藏

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

基于药代动力学/药效学模型确定新型TGF-β抑制剂LY2157299一水合物的治疗窗口

期刊:British Journal of Clinical Pharmacology

doi:10.1111/bcp.12256

Gueorguieva, Ivelina; Cleverly, Ann L; Stauber, Anja; Sada Pillay, N; Rodon, Jordi A; Miles, Colin P; Yingling, Jonathan M; Lahn, Michael M

发表日期：2014

文献求助收藏